Tina Vilsbøll - Publications, H-index & Citations

Back

Tina Vilsbøll

iqvia

87H-index

725Paper Count

3.5WCitation Count

Published Papers 368

Publication Date

Living with a transplanted liver is associated with diabetes

Scientific Reports

IF3.9

2026-04-27

OAAI

Julie Høgh; Nicoline Arentoft; Nicolai Aagaard Schultz; Ask Bock; Dina Leth Møller; Børge Grønne Nordestgaard; Shoaib Afzal; Niels Kristian Aagaard; Annette Dam Fialla; Peter Holland-Fischer; Thomas Peter Almdal; Jens Hillingsø; Allan Rasmussen; Tina Vilsbøll; Susanne Dam Nielsen

Save

Selenium supplementation in individuals with newly diagnosed Graves' hyperthyroidism: a double-blind, multi-centre RCT

European Thyroid Journal

IF4.3

2026-01-01

PREAI

Cramon, Per K.; Winther, Kristian H.; Boesen, Victor B.; Larsen, Camilla B.; Bjorner, Jakob B.; Nordqvist, Selma F.; Forman, Julie L.; Juul, Anne B.; Bach-Mortensen, Pernille; Knudsen, Nils; Nolsoe, Runa L.; Vilsboll, Tina; Andries, Alin; Gram, Jeppe; Nygaard, Birte; Demircan, Kamil; Chillon, Thilo S.; Schomburg, Lutz; Hegedus, Laszlo; Bonnema, Steen J.; Feldt-Rasmussen, Ulla; Rasmussen, Ase K.; Watt, Torquil

Save

Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1-based therapies: An expert consensus statement using a modified Delphi approach

Obesity Pillars

IF0

2025-12-01

OAAI

Sievenpiper, J. L.; Ard, J.; Bluher, M.; Chen, W.; Dixon, J. B.; Fitch, A.; Gigliotti, L.; Khunti, K.; Lecube, A.; Lean, M. E. J.; Mittendorfer, B.; Pfeiffer, A. F. H.; Ryan, D. H.; Vilsboll, T.; Van Gaal, L. F.

Save

Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use

Diabetes, Obesity and Metabolism

IF0

2025-11-25

OAAI

Tina Vilsbøll MD; Michael Stellfeld MD; Vanita R. Aroda MD; Sune Dandanell PhD; Jens-Peter David PhD; Ceyda T. P. Kristiansen PhD; Søren Rasmussen PhD; Fiona L. Roberts PhD; Laszlo Hegedüs MD

Save

Using glucagon receptor antagonism to evaluate the physiological effects of extrapancreatic glucagon in totally pancreatectomised individuals: a randomised controlled trial

Diabetologia

IF10.2

2025-09-18

OAAI

Caroline Trunk-Black Juel; Asger B. Lund; Sofie Hædersdal; Maria M. Andersen; Carsten P. Hansen; Jan H. Storkholm; Gerrit van Hall; Bolette Hartmann; Mette M. Rosenkilde; Camilla J. Kibsgaard; Flemming Dela; Nicolai J. Wewer Albrechtsen; Jens J. Holst; Tina Vilsbøll; Filip K. Knop

Save

Evaluating the role of alpha cell dysregulation in the progression to type 2 diabetes using mathematical simulations

Diabetologia

IF10.2

2025-09-09

OAAI

Vijaya Subramanian; Arthur S. Sherman; Jens J. Holst; Filip K. Knop; Tina Vilsbøll; Jonatan I. Bagger

Save

The Separate and Combined Effects of GIP, GLP-1, and GLP-2 on Markers of Bone Turnover in Type 2 Diabetes

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

IF5.1

2025-09-01

PREAI

Hansen, Josefine, V; Mathiesen, David S.; Christensen, Mikkel B.; Jorgensen, Niklas R.; Helsted, Mads M.; Bagger, Jonatan, I; Holst, Jens J.; Vilsboll, Tina; Knop, Filip K.; Lund, Asger B.

Save

The impact of plasma glucose decline rate on cardiac repolarisation in individuals with type 1 diabetes

diabetes obesity metabolism

IF0

2025-07-31

OAAI

Per G. Hagelqvist PhD; Christine R. Schwarz PhD; Kaisar Maytham BSc; Yasmin H. Hamid PhD; Tommi B. Lindhardt PhD; Bolette Hartmann PhD; Filip K. Knop PhD; Andreas Andersen PhD; Tina Vilsbøll DMSc

Save

HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis

diabetes obesity metabolism

IF0

2025-07-31

OAAI

Tina Vilsbøll MD; Maciej T. Malecki MD; Palash Sharma PhD; Vivian T. Thieu PhD; Krishna Karthik Chivukula MD; Jacek Kiljanski MD

Save

Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6

diabetes obesity metabolism

IF0

2025-07-24

OAAI

Jingmin Zhou MD; Mansoor Husain MD; Yang Li MMed; Wenyan Liu MMed; Zewei Shen MSc; Tina Vilsbøll MD; Junbo Ge MD

Save

Blood phosphatidylethanol measurements indicate GLP-1 receptor stimulation causes delayed decreases in alcohol consumption

ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH

IF2.7

2025-03-01

OAAI

Jensen, Mathias E.; Klausen, Mette K.; Bergmann, Marianne L.; Knudsen, Gitte M.; Vilsboll, Tina; Stove, Christophe; Fink-Jensen, Anders

Save

Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in type 2 diabetes according to baseline glucagon-like peptide-1 receptor agonist and sodium-glucose co-transporter-2 inhibitor use: A post hoc analysis of ONWARDS 1-5

DIABETES OBESITY & METABOLISM

IF5.7

2025-03-01

OAAI

Vilsboll, Tina; Fu, Ariel; Kellerer, Monika; Kumar, Bharath; Sogaard, Stinne Byrholdt; Goldenberg, Ronald

Save

Increased gallbladder emptying and reduced GLP-1 response in pregnancy with and without gestational diabetes mellitus

DIABETES OBESITY & METABOLISM

IF5.7

2024-11-14

PREAI

Gether, Ida M.; Andersen, Emilie S.; Foghsgaard, Signe; Ellegaard, Anne-Marie; Kelstrup, Louise; Sonne, David P.; Bronden, Andreas; Gillum, Matthew P.; Holst, Jens J.; Hartmann, Bolette; Rehfeld, Jens F.; Vilsboll, Tina; Knop, Filip K.

Save

Once Weekly Utreglutide (GL0034), a Glucagon-like Peptide-1 Receptor Agonist, at 4 x 450 μg Doses Reduces Blood Pressure, Lipids, and Body Weight in Post-menopausal Females: A Phase I Study

CIRCULATION

IF38.6

2024-11-12

PREAI

Thennati, Rajamannar; Burade, Vinod; Natarajan, Muthukumaran; Shahi, Pradeep; Nagaraja, Ravishankara; Agrawal, Sudeep; Duvauchelle, Thierry; Pratley, Richard; Thorens, Bernard; Vilsboll, Tina

Save

Comparing the Effectiveness of Different Dietary Educational Approaches for Carbohydrate Counting on Glycemic Control in Adults with Type 1 Diabetes: Findings from the DIET-CARB Study, a Randomized Controlled Trial

NUTRIENTS

IF5

2024-10-31

OAAI

Ewers, Bettina; Blond, Martin Baek; Bruun, Jens Meldgaard; Vilsboll, Tina

Save

Treatment trajectories for Danish individuals with type 2 diabetes in the era of emerging glucose-lowering therapies

DIABETES OBESITY & METABOLISM

IF5.7

2024-09-16

OAAI

Pottegard, Anton; Andersen, Jacob H.; Sondergaard, Jens; Rasmussen, Lotte; Kildegaard, Helene; Vilsboll, Tina; Thomsen, Reimar W.

Save

The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial

EUROPEAN JOURNAL OF ENDOCRINOLOGY

IF5.2

2024-07-25

PREAI

Hansen, Laura S.; Gasbjerg, Laerke S.; Bronden, Andreas; Dalsgaard, Niels B.; Bahne, Emilie; Stensen, Signe; Hellmann, Pernille H.; Rehfeld, Jens F.; Hartmann, Bolette; Wewer Albrechtsen, Nicolai J.; Holst, Jens J.; Vilsboll, Tina; Knop, Filip K.

Save

Glucagon Clearance Is Decreased in Chronic Kidney Disease but Preserved in Liver Cirrhosis

DIABETES

IF7.5

2024-07-25

PREAI

Grondahl, Magnus F. G.; Lange, Andreas H.; Suppli, Malte P.; Bagger, Jonatan I.; Thing, Mira; Gluud, Lise L.; Kofod, Dea H.; Hornum, Mads; van Hall, Gerrit; Trammell, Samuel A. J.; Grevengoed, Trisha J.; Hartmann, Bolette; Holst, Jens J.; Vilsboll, Tina; Christensen, Mikkel B.; Lund, Asger B.; Knop, Filip K.

Save

Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant-level meta-analysis of the ONWARDS 1-5 trials

DIABETES OBESITY & METABOLISM

IF5.7

2024-07-01

OAAI

Bajaj, Harpreet S.; Asbjoernsdottir, Bjoerg; Bari, Tanvir J.; Begtrup, Kamilla; Vilsboll, Tina; Rosenstock, Julio

Save

Clinical effects of SGLT2 inhibitors in seven persons with HNF1A-MODY (MODY3)

DIABETIC MEDICINE

IF3.4

2024-06-14

OAAI

Maagensen, Henrik; Haedersdal, Sofie; Krogh, Jesper; Hansen, Torben; Knop, Filip Krag; Thuesen, Anne Cathrine Baun; Vilsboll, Tina

Save

Research Directions